3-[[(2E)-2-(2-amino-1,3-thiazol-3-ium-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: 3-[[(2E)-2-(2-amino-1,3-thiazol-3-ium-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonate
• 化学式: C13H17N5O8S2
• 分子量: 435.4
• InChiKey: WZPBZJONDBGPKJ-CAOOACKPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  238
• 氢给体数：
  4
• 氢受体数：
  12

ADMET

毒理性

• 肝毒性

阿斯曲罗南具有与其他β-内酰胺类抗生素相似的全身毒性，但目前尚不清楚它是否可以像青霉素或头孢菌素一样引起肝脏损伤。在高剂量、静脉注射阿斯曲罗南治疗期间（10%至38%），无症状血清转氨酶升高很常见。酶异常通常是轻至中度的、无症状的、自限性的，不需要停药。与其它比较抗生素相比，阿斯曲罗南治疗期间酶升高的发生略为常见。由于没有报道过单个病例，因此可以认为由阿斯曲罗南引起的明显肝损伤和黄疸的情况极为罕见。因此，关于损伤的潜伏期或模式没有数据。有报道称在开始使用阿斯曲罗南后3到5天内出现明显的转氨酶升高的情况，但这些病例没有黄疸，且在停药后迅速缓解。

Aztreonam has systemic toxicities that are similar to those of other beta lactam antibiotics, but it is unclear whether it can cause hepatic injury similar to that of the penicillins or cephalosporins. Asymptomatic serum aminotransferase elevations are common during high dose, intravenous aztreonam therapy (10% to 38%). The enzyme abnormalities are usually mild-to-moderate, asymptomatic, self-limited and not requiring drug discontinuation. Enzyme elevations occur slightly more commonly during aztreonam therapy than with other comparative antibiotics. Cases of frank liver injury and jaundice attributable to aztreonam must be extremely rare as no individual cases have been reported. For this reason, there is no data regarding the latency or pattern of the injury. Instances of marked aminotransferase elevations within 3 to 5 days of starting aztreonam have been reported, but these cases were without jaundice and resolved rapidly once the drug was stopped.

来源:LiverTox

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：有限的信息表明，阿兹特罗胺在乳汁中产生的水平较低，预计不会对哺乳婴儿造成不良影响。偶尔有报道指出，婴儿的胃肠道菌群受到干扰，导致腹泻或鹅口疮，但这些影响尚未得到充分评估。一个由欧洲、澳大利亚和新西兰的呼吸专家组成的小组发现，吸入妥布霉素与哺乳相容。阿兹特罗胺适用于哺乳期母亲。 ◉ 对哺乳婴儿的影响：截至修订日期，未找到相关已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，未找到相关已发布信息。

◉ Summary of Use during Lactation:Limited information indicates that aztreonam produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with beta-lactams, but these effects have not been adequately evaluated. A task force respiratory experts from Europe, Australia and New Zealand found that inhaled tobramycin is compatible with breastfeeding. Aztreonam is acceptable in nursing mothers. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

文献信息

• [EN] AZTREONAM beta POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT<br/>[FR] POLYMORPHE < DE AZTREONAM AVEC TRES FAIBLE CONTENU EN SOLVANT RESIDUEL
  申请人：BIOGAL GYOGYSZERGYAR

  公开号：WO2004103999A1

  公开（公告）日：2004-12-02

  The invention relates to the β polymorph of Aztreonam, which contains less than 2.5 % by weight residual solvent and to a process of making said polymorph.

  该发明涉及阿特雷纳姆的β晶型，其含有少于2.5%重量的残留溶剂，并涉及制备该晶型的方法。
• Heteroaroylhydrazide derivatives of monocyclic beta-lactam antibiotics
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0342423A2

  公开（公告）日：1989-11-23

  Compounds having the formula and pharmaceutically acceptable salts thereof and possessing antibacterial activity, and interme­diates to compounds of formula I having the formula

  具有以下式子的化合物 及其具有抗菌活性的药学上可接受的盐类，以及具有以下式子的式 I 化合物的中间体
• Process and intermediates for Beta-lactams having aminothiazole (iminooxyacetic acid)acetic acid sidechains
  申请人：E.R. SQUIBB & SONS, INC.

  公开号：EP0464705A1

  公开（公告）日：1992-01-08

  Disclosed herein are processes for preparing a compound of the formula in which a novel compound of the formula is reacted with a beta lactam of the formula by treatment with a base, wherein the symbols are as defined in the specification.

  本文公开了制备式化合物的工艺 式的新型化合物的工艺。 与式中β-内酰胺反应 用碱处理，其中符号如说明书中所定义。
• New therapeutic approaches for treating Charcot-Marie-Tooth disease
  申请人：Pharnext

  公开号：EP2065038A1

  公开（公告）日：2009-06-03

  The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. More particularly, the invention relates to combined therapies for treating said disease by decreasing PMP22 expression in a subject.

  本发明涉及治疗夏科-玛丽-牙病及相关疾病的组合物和方法。更具体地说，本发明涉及通过降低受试者体内 PMP22 表达来治疗上述疾病的联合疗法。
• N-1 SUBSTITUTED SULFONYLAMINOCARBONYL, C-4 SUBSTITUTED MONOBACTAMS
  申请人：THE UPJOHN COMPANY

  公开号：EP0308416A1

  公开（公告）日：1989-03-29